A Phase 2, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy

Trial Profile

A Phase 2, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs KD 025 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Kadmon Corporation
  • Most Recent Events

    • 12 Apr 2017 Results published in a Kadmon Holdings media release.
    • 12 Apr 2017 Results published in the Cutting Edge section of the Journal of Immunology, according to a Kadmon Holdings media release.
    • 16 Nov 2016 Results assessing Psoriasis Area and Severity Index (PASI) scores and levels of cytokines in plasma sample, presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top